97 results about "Cellular component" patented technology

A method and device are provided for centrifugally separating plasma from whole blood in which whole blood is introduced into a flow circuit having a blood access device connected to a first tubing for drawing whole blood from a blood source and for flowing whole blood to a centrifugal separation chamber; a volume of saline is added to the whole blood as it flows through the first tubing to dilute the whole blood; the volume of saline added to the whole blood is tracked; the whole blood having saline added thereto is separated in the centrifugal separation chamber so that an interface is created between the plasma and added saline and the cellular components of the whole blood; the separated plasma and added saline is flowed from the centrifugal separation chamber to a collection container; and a volume for the plasma and added saline in the collection container is determined.

The invention discloses an implantable acellular matrix material and a preparation method thereof, and belongs to the field of biomedical materials. According to the method, natural animal tissues (such as pericardium, achilles tendon or small intestine submucosa) are used as raw materials, a low-temperature chemical combined decellularization treatment technology is adopted, and the method comprises the multi-step synergistic process of pre-cooling soaking balancing, low-temperature enzymolysis, low-concentration surfactant gradient permeation cleaning, low-temperature nuclease degradation, non-crosslinking sterilization and the like. Under the condition that the treatment temperature is strictly kept at 0-8 DEG C, cell components and genetic materials (the residual DNA content is 1t, and the dry weight is 8 ng / mg) are efficiently removed, and meanwhile the natural three-dimensional fine structure of an extracellular matrix (ECM), the integrity of collagen fibrils and key bioactive components (such as glycosaminoglycans (GAGs)) are reserved to the maximum extent. The host immunological rejection reaction of the obtained material is remarkably reduced, host cell ingrowth, vascularization and tissue function reconstruction can be effectively promoted after implantation, and the material is suitable for high-end implantation scenes such as soft tissue repair and regenerative medical stents.

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

A sequence of microscopic images is received that visualizes fluorescently labeled cellular components in living cells, each image containing an array of pixels. The images are segmented to identify one or more cells visualized therein. The machine learning model assigns a cell health condition score and / or a cell health subtype score for each pixel of a particular cell. These pixel-based cellular health scores and / or cellular health subtype scores are used to calculate an overall cellular health score and / or an overall cellular health subtype score for each cell. Data characterizing the calculated score is provided to the consumer application or process.

The present invention provides molecules that bind to cellular components or parts thereof (e.g., filaments or histones forming the cytoskeleton or nucleoskeleton) that are exposed to the extracellular environment upon cell death, which are specifically observed in diseased tissues, and simultaneously bind to target molecules on or in cells that act specifically in tissues where cell death is observed, such as diseased tissues, abnormal tissues, etc. The molecules of the present invention are useful as drugs that provide significant therapeutic or preventive effects while reducing side effects.

The present disclosure is generally directed to anchoring bridge nucleic acid probes in a polymer matrix, which are configured to hybridize to cellular nucleic acid, embedding in a polymer matrix, clearing cellular components including the cellular nucleic acid, contacting the anchored bridge probes with primary probes that hybridize with the bridge probes and imaging. The disclosure describes methods for imaging cellular RNA in an RNase insensitive method.

The sperm optimal tube comprises an upper tube, a lower tube and an inner tube, the upper tube and the inner tube are communicated, the upper tube is detachably connected with the lower tube, when the upper tube is connected with the lower tube, the lower tube is located outside the inner tube, one end of the inner tube is communicated with the upper tube, and the other end is provided with an opening allowing sperm to pass through, and a switch valve is arranged on the opening, the switch valve can be opened under the action of centrifugal force and closed after the centrifugal force stops. The device can effectively separate normal and active sperm, and especially because the switch valve is arranged, the sperm is allowed to flow out under the action of centrifugal force, and the switch valve is closed to seal the inner tube when the centrifugal force is eliminated, so that the abnormal sperm, the inactivated sperm and other cell components in the semen in the inner tube are prevented from entering the lower tube, and the complete separation of sperm with different activities is realized; the design of the inner tube, the upper tube and the lower tube facilitates the disassembly of the outer tube, the semen is more convenient to take out, and the mutual interference is avoided.

The present invention relates to a cellular component homogenate in liquid form, as well as to a cellular component homogenate in solid form, preferably as sprayed powder. Furthermore, the present invention relates to a homogenisation process for the preparation of said cellular component homogenate in liquid form and said cellular component homogenate in solid form, preferably as sprayed powder. Lastly, the present invention relates to a composition comprising said cellular component homogenate in solid form and, optionally, one or more pharmaceutical or food grade or cosmetic additives and excipients, for use in the pharmaceutical, nutraceutical, medical devices, foods for special medical purposes, dietary supplements and food industry both in the human and veterinarian field, as well as for use in the cosmetics industry.

The invention relates to a method for the generation of a TCR in a rodent, method comprising delivering an antigen presenting cell (APC) expressing an MHC-peptide complex to the rodent, wherein the MHC component of the MHC peptide is not expressed and generating T-cells to the MHC-peptide complex in the rodent. The method further comprises isolating or purifying the T-cell from the rodent. The MHC component is either allogenic or xenogenic and the MHC expressed in the rodent is a human HLA, such as HLA-A*02:01, HLA-A*11:01, HLA-A*03:01 or HLA-A*24:02. The rodent genome encodes a fully human TCR. The peptide is from a human antigen associated with disease, such as a tumour associated antigen. The rodent genome comprises human CD8 or chimeric CD8. The TCR sequence has been modified by up to 3 amino acids from that identified in the rodent. Also disclosed is a method for generating a TCR in a mouse, identifying the nucleic acid encoding the TCR and then mutating the sequence. The TCR is expressed in the form of a larger molecule. The APC is a synthetic antigen presenting cell.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

The application discloses a preparation method of a decellularized matrix and a product prepared by the method. The preparation method comprises the following steps: (1) washing a mammalian soft tissue to remove blood, lipids and impurities, and cutting the tissue into pieces with a thickness of 1-10 mm; (2) soaking the pieces in solution 1 for 6-48 h, and then soaking the pieces in solution 2 for 0.1-1 h; (3) treating the pieces in an ultrasonic water bath under the condition of a frequency of 20-40 kHz for 5-30 min; (4) water-bathing the pieces at 55-65 DEG C for 10-30 min; (5) sequentially washing the tissue with deionized water, a PBS buffer and ethanol, and washing the tissue with each solution for 1-3 times, each time for 10-30 min; and (6) freeze-drying the decellularized matrix material, and crushing the material at-80 DEG C to-20 DEG C to obtain a decellularized matrix powder. The preparation method significantly improves the cell component removal efficiency, effectively protects structural proteins such as collagen from being degraded in the freeze-drying and crushing processes, and ensures the integrity of the matrix in the aspects of morphology, structure and function, thereby providing a structural support and biological signal support for subsequent tissue repair.

Aspects of the present disclosure relate to the use of engineered host cells capable of producing protocatechuic acid (PCA). Aspects of the present disclosure also relate to compositions comprising engineered host cells capable of producing protocatechuic acid and / or cell constituents thereof, and the use of such compositions for altering and / or maintaining biological activity in a subject.

The utility model discloses a collecting and shaping structure for manufacturing a cell wax block, and relates to the field of pathology, the collecting and shaping structure comprises a shaping part for shaping cells and a water-permeable and cell-impermeable separating part, the shaping part is provided with an inlet end and an outlet end, the outlet end comprises a shaping section and an outlet, the shaping section is surrounded by a side wall to form a shape required to be endowed by the cells, and the separating part is provided with a water-permeable and cell-impermeable separating part. The outlet is located in the end, away from the inlet end, of the side wall, the section size of the shaping section is gradually increased or kept unchanged in the direction close to the outlet, and the separating part wraps the outlet and is detachably connected with the shaping section. By adopting the shaping component for shaping cells and the water-permeable and cell-impermeable separation component, an original sample is poured into the shaping component from the inlet end, and moisture in the original sample penetrates through the separation component through gravity, adsorption force or centrifugal force, so that the moisture is removed, and cell components are retained. In the process of removing moisture, cell components can be naturally enriched on the separation part according to the shape of the shaping section, so that shaping is synchronously completed.

The present invention relates to: a fish-derived acellular dermal matrix having improved tissue-to-tissue adhesion problems while ensuring biocompatibility by removing cellular components from fish-derived by-products; and a preparation method therefor.

Assays for determining the risk that a compound will induce liver injury in a subject are provided. A data set comprising a plurality of cellular component abundance values for a plurality of cellular components for each of a plurality of cells exposed to a test chemical compound for a first period of time is obtained. The data set is used to determine a pass value for each of a plurality of pass modules. Each module contains an independent subset of the plurality of cellular components. The pass values are input into one or more first models, thereby obtaining one or more first values. The abundance value is input into one or more second models, thereby obtaining one or more second values. The one or more first values and the one or more second values determine the risk that the compound will induce the liver injury.

A computational system and method for digital modeling of biochemical reactions within cardiac cells are disclosed. The system comprises processors and a computer-readable storage device with instructions to maintain biological data related to cardiac cell reactions and receive user selections via a user interface to configure a simulation. The user can select a cardiac cell class, and functions to load cellular components, generate enzyme activity, load specific enzymes, and perform enzymatic reactions. The system performs in silico experiments, predicts new biological data, and compiles this into configuration data. An enzyme activity model is generated and simulated under various conditions, including user-defined enzymatic dysregulation, to replicate and study cardiac physiology and pathology. The results, such as changes in energy metabolism parameters like glucose consumption and ATP usage, are outputted. The system provides a detailed and interactive platform for research and education in cardiac electrophysiology and disease.

The present invention relates generally to a method of detecting inhibitory effects of health supplements on serine protease in cell lines derived from human carcinomas. More, particularly, the present invention relates to inhibitory analysis of health supplementary products taken from market and / or chemically purified forms, in order to determine their competitors and / or inhibitory effects on serine protease such as trypsin so that these supplements can be used for the treatment once someone develop intense inflammatory reactions either due to infections like COVID-19 and / or pathological conditions such as cancer. The present invention further provides therapeutic applications for agents and / or condition which utilize human enzymatic system and / or cellular components for the development of pathological conditions.

To provide methods that provide a highly sensitive method for detecting rare cell types in a cell population and can overcome limited sensitivity in conventional methods of detecting stem cells caused by background expression of stem cell genes in non-stem cells and by cell loss during sample preparation.SOLUTION: A method of detecting the presence of or confirming the absence of target cells in a cell population comprises: specific steps (a) to (e).SELECTED DRAWING: None

The present invention relates to the strain Lactococcus lactis subsp. lactis CECT 31096, to its cellular components, metabolites, and secreted molecules, and to compositions comprising the above products, as well as to their uses as a medicament, preferably for the prevention and / or reduction of hypertension, or as a food composition or nutraceutical.

The application discloses a dislocation tooth storage and treatment box and a storage and treatment method. The box comprises a box body and a box cover. One side of the box cover is hinged to the box body, and the other side of the box cover is detachably connected to the box body. The box body is internally provided with a cleaning groove, a liquid storage groove, a tooth storage groove and a storage groove. The cleaning groove and the tooth storage groove penetrate through the bottom of the box body, and a sealing plug is detachably connected to the bottom of the box body. The cleaning groove, the liquid storage groove and the tooth storage groove are respectively detachably connected with a cleaning groove cover, a liquid storage groove cover and a tooth storage groove cover, which are fixedly connected to the box cover. A pair of tweezers is detachably connected to the storage groove. The scheme uses physiological saline to flush dirt on the dislocation tooth, uses HBSS to maintain and recombine cell components consumed by periodontal membrane cells, provides a good storage environment, uses HBSS containing ALN to treat the dislocation tooth to reduce root absorption after replantation, avoid bone adhesion and improve the replanting success rate.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention belongs to the technical field of bioprosthetic valves, and relates to a pericardial tissue decellularization method for bioprosthetic valve preparation, which comprises the following steps: decompressing to a target vacuum state by using a staged decompression method, carrying out vacuum-assisted decellularization treatment on pericardial tissue, washing the decellularized pericardial tissue, and drying to obtain the pericardial tissue decellularization method for bioprosthetic valve preparation. And finally, pressurizing the washed pericardial tissue to complete cell removal of the pericardial tissue. The washing treatment is carried out by adopting a periodic pressure difference auxiliary washing mode. According to the present invention, the integrity of the extracellular matrix is effectively maintained while the cell components are efficiently removed, and the residues during the decellularization process are reduced.

The invention belongs to the technical field of biological medicine, and discloses application of THY1 in diagnosis and prognosis of glioblastoma. According to the invention, a THY1-positive cancer-related fibroblast (THY1 + CAF) subgroup is identified in glioblastoma for the first time, and it is found that the subgroup and tumor blood vessels are highly co-localized in spatial distribution, and the abundance of the subgroup and the blood vessel density are significantly positively correlated; tHY1 + CAF is a key cell component for promoting angiogenesis in a GBM tumor microenvironment; tHY1 can be used as a marker of GBM specific CAFs, and is used for auxiliary diagnosis, prognosis evaluation (high THY1 + CAF may indicate worse prognosis and stronger angiogenesis phenotype) and curative effect monitoring of GBM. Meanwhile, the target THY1 or THY1 + CAF provides a brand-new and potential action target for developing a GBM new therapy for resisting angiogenesis and even remodeling an immunosuppressive microenvironment.

The invention discloses a panda colostrum cell separation and cryopreservation method and a cryoprotection solution, and belongs to the technical field of panda colostrum cryopreservation. The panda colostrum cell lysate comprises the following components in final concentration: 1.5-3wt% of honey, 1.5-3wt% of cane sugar, 20-30wt% of panda normal milk, 0.5-1.5 * 10 < 6 > cell equivalents / mL of panda colostrum cell lysate and normal saline. The invention further develops an active preparation special for the colostrum of the panda, and the active preparation is used in cooperation with the frozen colostrum. According to the preparation, natural cell components in colostrum of pandas are taken as core raw materials, the cryoprotectant is supplemented, and the preparation can be stably preserved in a liquid nitrogen environment after freezing treatment. When the frozen colostrum is used, the frozen colostrum is added into the frozen colostrum again after being unfrozen, so that cell components lost in the storage process of the frozen colostrum can be effectively supplemented, the biological activity of the frozen colostrum is closer to that of fresh colostrum, and the feeding effect of the frozen colostrum is improved.

The invention provides gradient bio-ink of a three-dimensional bionic corneal stroma scaffold and a 3D printing preparation process. The gradient bio-ink comprises 5-30 parts of a natural polymer matrix, 2-8 parts of a bioactive factor, 1-5 parts of a cell component, 1-10 parts of a light curing agent and 60-95 parts of normal saline. The natural polymer matrix contains methylacryloylated gelatin, a collagen / hyaluronic acid protein compound and chitosan, and the collagen / hyaluronic acid protein compound is prepared through lysyl oxidase cross-linking and visible light photocuring. After the bio-ink is prepared, an extrusion type 3D printer is adopted for printing layer by layer under specific conditions, ultraviolet irradiation is synchronously performed, and the three-dimensional bionic corneal stroma scaffold is prepared. The scaffold disclosed by the invention has good mechanical properties, light transmission and cell compatibility, can support directional differentiation of stem cells, and is suitable for cornea repair.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, durations and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

The present invention discloses a method for separating and freezing panda colostrum cells and a cryoprotectant, which belongs to the field of giant panda colostrum freezing preservation technology. The method comprises the following components at a final concentration: 1.5-3 wt% honey, 1.5-3 wt% sucrose, 20-30 wt% giant panda milk, 0.5-1.5×10 6 Cell equivalents / mL of giant panda colostrum cell lysate, and normal saline. The present invention also developed an active preparation specifically for giant panda colostrum for use in conjunction with frozen colostrum. This preparation uses the natural cell components in giant panda colostrum as the core raw material, and is supplemented with the above-mentioned cryoprotectant. After freezing, the preparation can be stably stored in a liquid nitrogen environment. When used, it is thawed and then added back to the frozen colostrum, which can effectively replenish the cell components lost in the frozen colostrum during storage, making it closer to the biological activity of fresh colostrum, thereby improving the feeding effect of frozen colostrum.

Disclosed herein include systems, methods, compositions, and kits for generating protected cellular component-binding compositions. There are provided, in some embodiments, protected cellular component-binding compositions comprising a cellular component-binding reagent associated with a protected cellular component-binding reagent specific oligonucleotide. A protected cellular component-binding reagent specific oligonucleotide can comprise a terminal blocked region. In some embodiments, the 3′ end of the protected cellular component-binding reagent specific oligonucleotide is incapable of being extended by a reverse transcriptase or a polymerase.

A system and method for distinguishing non-failing from failing cardiac fibroblasts (CFs) using advanced imaging techniques and machine learning (ML). The method involves staining CFs with fluorescent dyes to highlight key cellular components, such as nuclei and actin fibers. Images are analyzed to extract morphological features, which are then processed and normalized. A supervised ML system, trained on labeled CF data, classifies CFs based on phenotypic differences. The system enables accurate diagnosis of heart failure (HF), facilitates screening for therapeutic efficacy, and identifies antifibrotic agents by evaluating changes in CF phenotypes pre- and post-treatment.